Antibacterial Adjuvants for CAP-Resistant Gram-Negative Bacteria
Solution Overview
Problem
The rise of antibiotic-resistant gram-negative bacteria, particularly Pseudomonas aeruginosa, poses a significant threat due to limited treatment options and increasing resistance to cationic antimicrobial peptides, necessitating new strategies to combat bacterial infections effectively.
Innovation Solution
Development of compounds of formula I, which can be used in conjunction with cationic antimicrobial peptides (CAPs) to inhibit the growth of gram-negative bacteria by modifying the outer membrane surface charge and reducing the minimum inhibitory concentration of CAPs, thereby enhancing their susceptibility.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cationic antimicrobial peptides (CAPs) are used to treat gram-negative bacteria, then antibacterial activity is achieved, but bacteria develop resistance reducing treatment effectiveness
Solution Approach 1:
The patent introduces small molecule adjuvants as intermediary compounds that work in combination with CAPs. These adjuvants bind to the outer membrane of gram-negative bacteria and facilitate CAP penetration, effectively reversing resistance mechanisms. The adjuvant acts as a mediator that enables the CAP to overcome bacterial defense mechanisms, restoring treatment effectiveness against resistant strains.
Solution Approach 2:
The patent creates a composite treatment system combining small molecule adjuvants with cationic antimicrobial peptides. This composite approach leverages the membrane-targeting capability of the adjuvant and the bactericidal activity of the CAP, producing a synergistic effect that overcomes resistance while maintaining low concentrations of both components.
2Reliability
If CAP concentration is increased to overcome resistance, then antibacterial activity improves, but toxicity to host cells increases
Solution Approach 1:
The patent fundamentally changes the concentration parameter relationship by introducing an adjuvant that enables CAP activity at low concentrations. Instead of increasing CAP concentration to overcome resistance, the adjuvant modifies the system parameters to achieve high antibacterial activity at sub-toxic CAP levels, thereby decoupling efficacy from toxicity.
Solution Approach 2:
The small molecule adjuvant serves as an intermediary that amplifies CAP effectiveness. By binding to the outer membrane and facilitating CAP entry, the adjuvant allows trace amounts of CAP to achieve potent bactericidal activity, eliminating the need to increase CAP concentration to toxic levels.
3Reliability
If small molecule adjuvants are used to enhance CAP activity, then susceptibility of resistant bacteria increases, but compound complexity increases
Solution Approach 1:
The patent modifies chemical parameters by designing small molecule adjuvants with specific structural features (amphipathic character, membrane affinity) that enable their function. These parameter-optimized compounds achieve complex biological effects through relatively simple molecular structures, balancing efficacy with structural feasibility.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively inhibit the growth of CAP-resistant gram-negative bacteria, including P. aeruginosa, by maintaining ionic interactions with the outer membrane surface and reducing the required concentration of CAPs, offering a potential treatment for multidrug-resistant strains.
Implementation Method 1
maintaining ionic interactions with the outer membrane surface
Data Source
AI summary
In one aspect, compounds and methods are described herein for treating gram negative bacteria having resistance to cationic antimicrobial peptides. In some embodiments, for example, compounds of formula I are provided. In another aspect, a treatment for a gram negative bacterial infection comprises a cationic antimicrobial protein (CAP) in conjunction with a compound of formula I.